Patents by Inventor Olivier Meilhac

Olivier Meilhac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS
    Publication number: 20230302162
    Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
    Type: Application
    Filed: December 5, 2022
    Publication date: September 28, 2023
    Inventors: Olivier MEILHAC, Emmanuelle JESTIN, Florian GUIBBAL, Sébastien BENARD
  • Radiolabeled Darapladib and analogs thereof and their use as imaging compounds
    Patent number: 11583596
    Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: February 21, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNION
    Inventors: Olivier Meilhac, Emmanuelle Jestin, Florian Guibbal, Sébastien Benard
  • RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS
    Publication number: 20200276337
    Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
    Type: Application
    Filed: September 26, 2018
    Publication date: September 3, 2020
    Inventors: Olivier MEILHAC, Emmanuelle JESTIN, Florian GUIBBAL, Sébastien BENARD
  • HDL comprising a therapeutic agent and use in therapy
    Publication number: 20160317443
    Abstract: The present invention provides an HDL comprising an agent selected from the group consisting of antiproteases, antioxidants, antimitotics, anti-apoptotic agents and agents involved in the iron metabolism for use as a medicament.
    Type: Application
    Filed: July 13, 2016
    Publication date: November 3, 2016
    Inventor: Olivier Meilhac
  • Method of reducing side effects associated with administration of tissue plasminogen activator (tPA)
    Patent number: 9415094
    Abstract: Provided is an HDL comprising an agent selected from the group consisting of antiproteases, antioxidants, antimitotics, anti-apoptotic agents and agents involved in the iron metabolism for use in methods of reducing side effects associated with administration of tissue plasminogen activator (tPA) in subjects in need of treatment.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: August 16, 2016
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventor: Olivier Meilhac
  • HDL COMPRISING A THERAPEUTIC AGENT AND USE IN THERAPY
    Publication number: 20120177626
    Abstract: The present invention provides an HDL comprising an agent selected from the group consisting of antiproteases, antixoxidants, antimitotics, anti-apoptotic agents and agents involved in the iron metabolism for use as a medicament.
    Type: Application
    Filed: January 13, 2012
    Publication date: July 12, 2012
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventor: Olivier Meilhac